Ariana Pelosci

Trevor M. Feinstein, MD, discussed the phase 3 DUBLIN-3 trial evaluating docetaxel with or without plinabulin for patients with EGFR wild-type stage IIIB/IV non–small cell lung cancer.

A real-world, prospective cohort study identified independent predictors may increase the risk of early mortality in patients with newly diagnosed multiple myeloma.

Results from the phase 1/2 ARROW trial showed robust and durable responses in patients with RET fusion–positive cancer treated with pralsetinib.

Based on results from the phase 3 MOMENTUM trial, the FDA has accepted a new drug application of momelotinib for patients with myelofibrosis.

Pediatric and adult patients who have β -thalassemia and need regular red blood cell infusions may now receive betibeglogene autotemcel, which has been approved by the FDA.

Findings from a recent study show that a neutrophil-to-lymphocyte ratio of less than 6 before treatment was correlated with improved overall survival for patients with endometrial cancer.

Results from the second interim analysis of the phase 3 TROPiCS-02 trial showed significantly improved overall survival among patients with hormone receptor–positive, HER2-negative metastatic breast cancer who were given sacituzumab govitecan vs physician’s choice of treatment.

Patients with newly diagnosed acute myeloid leukemia had longer overall survival with a modified dosing schedule of venetoclax plus a hypomethylating agent.

The primary end point of improved progression-free survival was met in the phase 3 DESTINY-Breast02 trial when patients with HER2-positive unresectable and/or metastatic breast cancer were given trastuzumab deruxtecan vs physician’s choice of therapy.

Regular approval has been granted to capmatinib for the treatment of patients with metastatic non–small cell lung cancer whose tumors harbor a MET exon 14 skipping mutation.

At ASCO 2022, Roy S. Herbst, MD, PhD, reviews a substudy of the phase 2 Lung-MAP trial which investigates ramucirumab plus pembrolizumab for patients with advanced non–small cell lung cancer who demonstrated resistance to previous immunotherapy.

Elacestrant was granted priority review by the FDA for the treatment of estrogen receptor–positive, HER2-negative metastatic breast cancer.

Rafael Fonseca, MD, discusses use of elranatamab in patients with relapsed/refractory multiple myeloma and ongoing research into bispecific antibodies.

The phase 3 RATIONALE 301 trial examining first-line tislelizumab vs sorafenib in unresectable hepatocellular carcinoma met the primary end point of noninferior overall survival.

Overall survival, the primary end point of the phase 3 FRESCO-2 trial, was met when patients were given fruquintinib vs placebo for advanced refractory metastatic colorectal cancer.

Patients with treatment-naïve metastatic non–small cell lung cancer who received either sintilimab or pembrolizumab monotherapy, or either agent combined with chemotherapy, experienced comparable outcomes.

The European Commission approved olaparib as monotherapy or in combination with endocrine therapy for patients with germline BRCA1/2-mutant, HER2-negative high-risk early breast cancer.

Based on results from the phase 3 DESTINY-Breast04 trial, the FDA has approved fam-trastuzumab deruxtecan-nxki as an intravenous infusion for patients with unresectable or metastatic HER2-low breast cancer.

Acalabrutinib tablet formulation was approved by the FDA for patients with chronic lymphocytic leukemia/small lymphocytic leukemia and relapsed or refractory mantle cell lymphoma.

Results from the phase 3 KEYNOTE-921 trial showed the primary end points of overall survival and radiographic progression-free survival were not met despite a trend towards improvement following treatment with pembrolizumab and docetaxel in patients with metastatic castration-resistant prostate cancer.

Findings from the planned futility interim analysis of the phase 3 INTERLINK-1 trial has led to the study’s termination after monalizumab and cetuximab did not meet efficacy end points in recurrent or metastatic squamous cell carcinoma in the head and neck.

Results from the phase 3 IMscin001 trial indicated that atezolizumab given subcutaneously vs intravenously yielded non-inferior pharmacokinetics for patients with immunotherapy-naïve locally advanced or metastatic non–small cell lung cancer.

Based on results from a phase 3 trial, the FDA has accepted a biologics license application for and granted priority review to omidubicel for those with hematologic malignancies who require allogenic hematopoietic stem cell transplant.

Patients with stage III non–small cell lung cancer and baseline grade 1 radiation pneumonitis post-chemotherapy could benefit from treatment with durvalumab.

Kim A. Reiss Binder, MD, spoke about the phase 1 CARISMA trial which investigated CAR macrophages in HER2-overexpressing solid tumors.

Results from a phase 2 study indicated that adding elotuzumab to carfilzomib, lenalidomide, and dexamethasone with a minimal residual disease–adapted design boosted responses for those with newly diagnosed multiple myeloma.

Investigators reported that vaccinated patients had a higher rate of grade 2/3 cervical neoplasia due to non–vaccine preventable human papillomavirus compared with unvaccinated patients, an event commonly termed clinical unmasking.

Treatment with radiotherapy for head and neck cancer resulted in taste dysfunction during treatment and 3 months thereafter, although reduction in oral cavity intensity-modulated radiotherapy dose may result in early taste function recovery.

Results from a phase 1b/2 trial indicated that niraparib plus nivolumab yielded superior progression-free survival at 6 months vs niraparib and ipilimumab for patients with platinum-sensitive advanced pancreatic cancer.

Elotuzumab, lenalidomide, high-dose melphalan, as well as umbilical cord blood–derived natural killer cells and autologous stem cell transplant demonstrated tolerability and improved transplant outcomes for high-risk multiple myeloma.